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infants with botulism
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Abstract
Background: Infant botulism is the most prevalent form of botulism in the USA, representing 68.5 % of cases
reported from 2001–2012. Infant botulism results when botulinum toxin-producing clostridia (BTPC) colonize
the infant gut with concomitant in vivo production of the highly potent botulinum neurotoxin (BoNT). The
gut microbiota of infants with botulism is largely uncharacterized; therefore, it remains unclear whether the
microbiota profile of these patients are distinct in composition, abundance, or diversity. To address this
uncertainty, we employed 16S rRNA gene profiling to characterize the fecal microbiota in 14 stool samples
among laboratory-confirmed and non-confirmed infant botulism cases.
Results: Seven bacterial phyla were identified among all 14 infant stool samples examined. Compared to
samples from non-confirmed cases, the fecal microbiota of infant botulism patients displayed significantly
higher Proteobacteria abundance. Of the 20 bacterial families identified, Enterobacteriaceae was significantly
more abundant in samples from infants with botulism. Firmicutes abundance and the abundance ratio of
Firmicutes/Proteobacteria was significantly lower in samples from infants with botulism. Lactobacillus spp.
abundance was notably reduced in 12 of the 14 samples. Clostridium botulinum and Clostridium baratii were
identified in low relative abundances in confirmed and non-confirmed samples based on their 16S rRNA
gene profiles, although their toxigenicity remained undetermined. No significant differences were observed
in the number of operational taxonomic units (OTUs) observed or in fecal microbiota diversity between
laboratory-confirmed and non-confirmed samples. Correlations between individual phylum abundances and
infant age were variable, and no significant differences were shown in number of OTUs observed or in fecal
microbiota diversity between samples delineated by overall mean age.
Conclusions: Significant differences in Proteobacteria, Firmicutes, and Enterobacteriaceae abundances were
identified in the fecal microbiota of infants with botulism when compared to samples from non-confirmed
cases. Fecal microbiota diversity was not significantly altered in infants with botulism, and a limited presence
of BTPC was shown. It could not be determined whether the fecal microbiota profiles shown here were
comparable prior to patient illness, or whether they were the direct result of infant botulism. The results of
this study do, however, provide a detailed and descriptive observation into the infant gut microbiota after
intestinal colonization by BTPC.
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Background
From 2001 to 2012, the National Botulism Surveillance
System reported an average of 142 cases per year of botu-
lism in the USA [1]. Infant botulism is responsible for
68.5 % of these cases. Each year, the National Botulism
Laboratory Team (NBLT) at the Centers for Disease
Control and Prevention (CDC) investigates approximately
20 suspected cases of infant botulism submitted by states
across the USA. First described in 1976 [2], infant botu-
lism occurs in children less than 1 year old, and infant
susceptibility to gut colonization of botulinum neurotoxin
(BoNT) producing clostridia (BTPC) may be associated
with perturbations of the developing infant gut microbiota
[3]. Strains of Clostridium botulinum, Clostridium baratii,
and Clostridium butyricum have each been implicated as
the causative agents in infant botulism cases. Positive con-
firmation of infant botulism is established when BoNT
and/or isolates of BTPC are detected in the stool.
Compared to adults, infants harbor an intestinal micro-
biota (i.e., the assemblage of microorganisms which
occupy the gut) that is transient and minimally complex
[4, 5]. A number of factors are known to influence the
microbial composition within the infant gut including age
[6–8], mode of delivery [9, 10], diet [11–13], antibiotic use
[14–16], and disease [17, 18], making it difficult to delin-
eate their respective effects. An important function of the
microbiota beyond digestion and metabolism is to prevent
the propagation of pathogenic microorganisms [19–21]. It
has been suggested that alterations of the developing
infant gut microbiota may suppress BTPC colonization
resistance, thus increasing susceptibility to botulism in
certain individuals. Although studies using mouse models
appear to support this claim, the etiology of this process
remains unclear [22, 23].
Some risk factors identified for infant botulism include
honey consumption, breastfeeding status, and living in a
rural area [24–28]. Many of these risk factors have been
shown to independently influence the microbiota in both
healthy and diseased infants. However, delineating the
degree of influence of botulism on the infant gut micro-
biota from disease-independent factors is a difficult chal-
lenge and not the focus of this study. Our aim was to
provide a detailed descriptive analysis of the fecal micro-
biota of infants with botulism and to identify any signifi-
cant alterations in bacterial abundance, composition,
and/or diversity among samples from confirmed and
non-confirmed infant botulism cases. To characterize
the prokaryotic members of the infant gut microbiota,
we targeted the hypervariable V3 region of the 16S
rRNA gene for high-throughput sequencing and per-
formed extensive downstream taxonomic analysis. This
methodological approach allowed for a thorough and
descriptive taxonomic characterization of the patient
fecal microbiota and provided a means to evaluate
disparities between the gut microbiota of infants with
botulism and the gut microbiota of infants from non-
confirmed botulism cases.
Results
Evaluation of amplification and sequencing bias
Each of the five phyla from the mock community sample
were successfully identified from sequence read analysis
(Fig. 1). Overall mean absolute percent error (MAPE)
for abundance quantification of the microbial mock
community was 14.4 % (SD ± 33.1). Overall error was
heavily skewed (MAPE = 74 %; SD ± 10) toward two
phyla (Bacteroidetes and Deinococcus-Thermus), which
represented the bottom 10 % of total phylum abundance.
Abundance quantification of the top 90 % of phyla re-
sulted in a MAPE of 7.6 % (SD ± 0.27). Results from
mock community sequencing indicated that the study
methodology employed was largely effective for phylum-
Fig. 1 Histograms of mock community DNA-sequencing results. Expected phylum abundance percentages were calculated by classifying each of
the 20 known bacterial species into their respective phylum. Observed phylum abundance percentages were calculated by assigning 16S rRNA
gene sequence reads to representative taxonomy by alignment with Greengenes ribosomal database using an OTU definition of 97 % sequence
homology or greater with a minimum cluster size of 3
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level taxonomic analysis; however, the percent error may
increase when quantifying underrepresented phyla.
Sample and patient characteristics
We analyzed 14 infant stool samples from 14 patients
representing a broad range of ages. Eight samples were
associated with laboratory-confirmed botulism cases
representing BoNT serotypes A, B, and F (designated as
“confirmed”), and six samples were from cases where no
laboratory confirmation of botulism could be made (des-
ignated as “non-confirmed”). Mean patient age across all
14 samples was 87.9 days (SD ± 98.3). Mean patient age
in confirmed samples was 68.0 days (SD ± 88.7), and
mean patient age in non-confirmed samples was
114.3 days (SD ± 120.8). There was no significant
difference in patient age between confirmed and non-
confirmed samples (p = 0.22; alpha = 0.05). Coded
sample names, BoNT type detected, quantitative PCR
results, and patient ages at the time of sample collec-
tion are listed in Table 1. No additional patient or
sample metadata was available for these cases.
Taxonomic and statistical analysis of fecal microflora
Sequence read statistics and alpha diversity metrics from
16S rRNA gene sequencing are listed in Table 2. The
number of operational taxonomic units observed (OTU;
defined as a subset of 3 or more sequence reads that
share 97 % or greater sequence homology) was lowest
for CDC68053 and highest for CDC68083 with an
average number of OTUs per sample of 902.4 (SD ±
502.0). There was no significant difference in number of
OTUs observed between confirmed and non-confirmed
samples (p = 0.61; alpha = 0.05). Shannon diversity index,
a measure of bacterial richness and evenness, revealed
that the fecal microbiota from sample CDC68083 was
highest in bacterial diversity while sample CDC68116
displayed lowest diversity. Fecal microbiota diversity was
not significantly different between confirmed and non-
confirmed samples (p = 0.52; alpha = 0.05).
Phylum-level taxonomic analysis of the fecal microflora
revealed the presence of 7 bacterial phyla which included
Firmicutes, Proteobacteria, Actinobacteria, Bacteroidetes,
Tenericutes,Verrucomicrobia, and Fusobacteria (Fig. 2). A
small percentage of sequence reads (range = 0.02–0.39 %)
could not be assigned to a phylum and therefore desig-
nated as “Unassigned”. Firmicutes percent abundance was
significantly lower (p = 0.01; alpha = 0.05) in the fecal
microbiota of botulism-confirmed samples (x̅ = 25.4 %;
SD ± 24.6) compared to non-confirmed samples (x̅ =
63.8 %; SD ± 27.0), and Proteobacteria abundance was sig-
nificantly higher (p = 0.01; alpha = 0.05) in confirmed sam-
ples (x̅ = 47.6 %; SD ± 31.1) compared to non-confirmed
samples (x̅ = 8.6 %; SD ± 15.6). No other phylum displayed
a significant difference in abundance between confirmed
and non-confirmed samples. The ratio of Firmicutes/Pro-
teobacteria was 515 times lower (p = 0.01, alpha = 0.05) in
confirmed samples (x̅ = 1.1; SD ± 1.7) than in non-
confirmed samples (x̅ = 586.6; SD ± 1392.2) (Fig. 3), and
the ratio of Firmicutes/Bacteroidetes was 1.4 times lower
(p = 0.11, alpha = 0.05) in confirmed samples (x̅ = 7292.6;
SD ± 17459.2) than in non-confirmed samples (x̅ =
10563.8; SD ± 16825.8) (Fig. 4).
Family-level taxonomic analysis of the fecal microflora
in the infant stool samples revealed the presence of 20
bacterial families (Table 3). Sequence reads that could not
be assigned to a bacterial family, and families with <1.0 %
abundance in each of the 14 samples, were designated as
“Other”. The Gammaproteobacteria family Enterobacteri-
aceae displayed significantly higher abundance (p = 0.02,
alpha = 0.05) in confirmed samples (x̅ = 44.0 %; SD ± 33.5)
compared to non-confirmed samples (x̅ = 8.4 %; SD ±
15.7) (Fig. 3). No other bacterial family displayed a signifi-
cant difference in abundance between confirmed and
non-confirmed samples.
Based on 16S rRNA gene taxonomy, C. botulinum
was identified in 6 of the 8 confirmed samples and 2
of the 6 non-confirmed samples, with relative abun-
dances ranging from <0.001 to 0.01 % of the overall
bacterial community where detected (Table 4). C. bar-
atii was identified in 5 of the 8 confirmed samples
and 2 of the 6 non-confirmed samples with relative
abundances ranging from <0.001 to 0.003 % of the
overall bacterial community where detected (Table 4).
Table 1 Patient characteristics and sample properties of the 14
stool samples examined for this study
Stool Sample Patient age (days) BoNT typea PCR result
1 CDC68129 14 Type B bont/B
2 CDC68058 16 Type F bont/F
3 CDC69068 21 Type B bont/B
4 CDC68083 25 Type Ab bont/A bont/B
5 CDC68116 28 Type A bont/A
6 CDC68192 50 Type B bont/B
7 CDC68090 120 Type B bont/B
8 CDC68126 270 Type B bont/B
9 CDC68053 17 None Negative
10 CDC69114 46 None Negative
11 CDC68112 63 None Negative
12 CDC68122 90 None Negative
13 CDC69062 120 None Negative
14 CDC69078 350 None Negative
aBoNT type refers to the botulinum toxin type detected in each corresponding
sample via mouse bioassay
bIn this case, the isolate of BTPC not only produced BoNT serotype A, but also
harbored an unexpressed gene encoding bont/B
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Table 2 Sequence read statistics and alpha diversity metrics for each of the 14 stool samples examined for this study
Botulism Sample Total number of readsa Number of reads passing quality filteringa Number of OTUs observeda Shannon diversity indexa
Confirmed CDC68129 747314 460195 496 2.3
CDC68058 796510 376891 850 2.9
CDC69068 706703 440769 637 2.5
CDC68083 720976 510882 2242 4.4
CDC68116 760653 543541 475 0.7
CDC68192 864853 446933 928 3.4
CDC68090 589121 369066 1615 3.2
CDC68126 496815 396233 994 3.0
Non-confirmed CDC68053 595735 433809 418 1.5
CDC69114 723322 496246 517 2.4
CDC68112 715786 285335 670 2.2
CDC68122 831044 602856 676 2.1
CDC69078 619394 392261 1117 3.8
CDC69062 819457 412327 998 3.4
aHighest and lowest value in each column recorded in bold
Fig. 2 Stacked histograms illustrating phylum-level bacterial composition of the 14 stool samples. Ion Torrent 16S rRNA gene sequence reads were
assigned to representative taxonomy by alignment with Greengenes ribosomal database using an OTU definition of 97 % sequence homology or
greater with a minimum cluster size of 3
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Samples were re-grouped relative to mean patient age
of all 14 samples to examine the association between age
and phylum-level abundance. Nine samples were col-
lected from patients younger than the overall mean pa-
tient age (collectively referred to as the “younger”
group), and 5 samples were collected from patients older
than the overall mean patient age (collectively referred
to as the “older” group). Proteobacteria abundance was
significantly higher (p = 0.04; alpha = 0.05) among the
younger group (x̅ = 50.3 %; SD ± 28.5) compared to the
older group (x̅ = 8.8 %; SD ± 8.2) (Fig. 5). No other
phylum displayed a significant difference in abundance
between the younger and older group. The average ratio
of Firmicutes/Proteobacteria was 170 times lower (p =
0.13; alpha = 0.05) in the younger group (x̅ = 4.1; SD ±
9.3) compared to the older group (x̅ = 698.3; SD ±
1526.2), and the average ratio of Firmicutes/Bacteroi-
detes was 6.0 times lower (p = 0.57; alpha = 0.05) in the
younger group (x̅ = 13671.8; SD ± 20643) compared to
the older group (x̅ = 2287.1; SD ± 3028.2) (data not
shown). There was no significant difference (p = 0.28;
alpha = 0.05) in number of OTUs observed between the
younger infant group and the older infant group. Fecal
microbiota diversity was not significantly different be-
tween the younger infant group and the older infant
group (p = 0.20; alpha = 0.05).
Redundancy analysis (RDA) was used to explore asso-
ciations among infant microbiota composition and abun-
dance, and to examine the influence of infant age on
sample variance (Fig. 6) [29]. Taxonomically unclassified
data were excluded from RDA analysis, as was data
representing the phylum Fusobacteria which was only
detected in trace abundance (<0.002 %) in one sample.
RDA explained 83.7 % of all variation among samples.
Overall sample variance was produced by the com-
bined effect of bacterial abundance, bacterial compos-
ition, and infant age (F = 3.5; p = 0.048; alpha = 0.05).
RDA confirmed a negative correlation between Pro-
teobacteria abundance and infant age, and positive
correlations between infant age and Tenericutes, Acti-
nobacteria. Bacteroidetes, and Verrucomicrobia abun-
dance. RDA revealed that Proteobacteria abundance
was positively correlated with 7 samples (CDC68116,
CDC68058, CDC68068, CDC68129, CDC68053,
CDC68083, and CDC69114). Three samples (CDC68126,
CDC69078, and CDC68090) were positively correlated to
Tenericutes, Actinobacteria,Verrumicrobia, and to a lesser
extent Bacteroidetes abundance. The phylum Firmicutes
displayed a negative correlation to all other phyla by
RDA, and displayed a positive correlation with samples
CDC69062, CDC68122, CDC68112, and CDC68192.
The influence of age was weighted most heavily on
Fig. 3 Box plots of the ratios of Firmicutes/Bacteroidetes (a) and Firmicutes/Proteobacteria (b) in confirmed and non-confirmed samples. Abundance
measurements based on 16S rRNA sequence reads and assigned by alignment with Greengenes ribosomal database using an OTU definition of
97 % sequence homology with a minimum cluster size of 3. Outliers within each group are indicated by the circular points on the plots
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sample CDC69078 which was 7.2 times greater than its
effect on all other samples.
Discussion
Characterizing the fecal microbiota in infants with botu-
lism provides another step toward understanding the
link between the infant gut microbiota and this disease.
Although enteric diseases can produce discernable, if
not predictable, alterations to the bacterial gut micro-
biota [30], it can also be influenced by a wide variety of
disease-independent perturbations [31]. The findings of
our study revealed the fecal microbiota of infants with
botulism was characterized by an over-enrichment of
Proteobacteria with low Firmicutes abundance. This find-
ing highlighted a significant disparity between confirmed
and non-confirmed samples with a clear deviation from a
more traditional healthy-infant microbiota profile [16].
Previous studies have reported reduced Firmicutes abun-
dance with a concomitant increase in Proteobacteria
abundance in response to disease-mediated alterations of
the gut microflora [32, 33]. Firmicutes are often highly
represented in the gut microbiota of healthy individuals
and can be reduced in illness [34], while a significant in-
crease in Proteobacteria abundance can lead to gastro-
intestinal inflammation in response to environmental and
genetic factors [35].
A notable disparity was identified among the relative
proportions of Lactobacillus spp. identified among sam-
ples. The genus Lactobacillus contains over 180 species
of bacteria, many of which are commonly found propa-
gating the microbiota of healthy infants. Lactobacillus
spp. abundance was markedly reduced (mean relative
abundance = 0.2 %; SD ± 0.004) in the fecal microbiota of
all 8 confirmed samples, and 4 of the 6 non-confirmed
samples (data not shown). Similar reductions have been
reported in previous studies investigating the fecal
microbiota of infants [5, 36–38]. Among these reports, it
was suggested that a variety of factors (e.g. caesarian deliv-
ery, aggressive antibiotic treatment, long-term incubation)
may combine to suppress Lactobacillus colonization, sig-
nificantly delay the establishment of beneficial bacteria, and
increase susceptibility to enteric pathogen colonization.
Fig. 4 Box plot indicating the percent abundance of the bacterial family Enterobacteriaceae in confirmed and non-confirmed samples. Abundance
measurements based on 16S rRNA sequence reads and assigned by alignment with Greengenes ribosomal database using an OTU definition of 97 %
sequence homology with a minimum cluster size of 3. A single outlier within the non-confirmed group is indicated by the circular point on the plot
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Table 3 Family-level percent bacterial composition for each of the 14 stool samples examined in this study
Confirmed samples b Non-confirmed samplesb
Phylum Family CDC68129 CDC68058 CDC69068 CDC68083 CDC68116 CDC68192 CDC68090 CDC68126 CDC68053 CDC69114 CDC68112 CDC68122 CDC69062 CDC69078
Actinobacteria Actinomycetaceae 0.0 % 0.0 % 0.1 % 0.0 % 1.0 % 2.4 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.4 % 0.0 % 0.0 %
Bifidobacteriaceae 6.1 % 0.0 % 24.6 % 4.6 % 0.0 % 0.0 % 51.9 % 53.5 % 0.0 % 0.0 % 19.3 % 0.0 % 6.7 % 48.2 %
Coriobacteriaceae 1.2 % 0.0 % 5.4 % 0.2 % 0.1 % 1.6 % 0.0 % 0.0 % 0.0 % 12.7 % 0.0 % 0.0 % 0.5 % 0.8 %
Bacteroidetes Bacteroidaceae 0.0 % 0.0 % 0.1 % 21.4 % 0.3 % 0.0 % 0.0 % 20.5 % 0.0 % 0.3 % 0.0 % 0.0 % 0.0 % 1.4 %
Rikenellaceae 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 4.2 %
Sphingobacteriaceae 0.0 % 0.0 % 0.0 % 15.7 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 %
Firmicutes Paenibacillaceae 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 3.7 % 0.0 %
Planococcaceae 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 21.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 40.2 % 0.0 %
Enterococcaceae 22.3 % 20.4 % 14.8 % 19.2 % 0.9 % 42.8 % 7.1 % 0.4 % 0.0 % 10.0 % 72.9 % 8.9 % 34.0 % 0.1 %
Lactobacillaceae 0.0 % 0.0 % 0.0 % 0.0 % 0.3 % 1.3 % 0.0 % 0.0 % 31.4 % 0.0 % 0.6 % 69.6 % 0.0 % 0.0 %
Clostridiaceae 3.5 % 0.1 % 0.3 % 0.1 % 0.1 % 11.9 % 4.1 % 0.2 % 0.0 % 35.1 % 0.0 % 4.4 % 0.5 % 0.8 %
ClostridialesFamilyXI 0.0 % 0.0 % 3.2 % 0.0 % 0.2 % 0.4 % 0.2 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 12.1 % 0.0 %
Lachnospiraceae 0.2 % 0.0 % 0.0 % 0.2 % 0.1 % 23.0 % 0.0 % 0.8 % 0.0 % 1.1 % 0.0 % 8.3 % 1.1 % 36.1 %
Ruminococcaceae 1.3 % 0.0 % 0.0 % 0.4 % 0.1 % 0.2 % 0.0 % 0.2 % 0.0 % 0.2 % 0.0 % 0.0 % 0.5 % 3.5 %
Proteobacteria Sphingomonadaceae 0.0 % 0.0 % 0.0 % 2.7 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 %
Comamonadaceae 0.0 % 0.0 % 0.0 % 18.4 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.2 % 0.0 % 0.0 %
Desulfovibrionaceae 0.0 % 0.0 % 0.0 % 4.1 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 %
Enterobacteriaceae 65.2 % 78.7 % 51.1 % 9.1 % 96.3 % 15.7 % 14.4 % 21.5 % 0.1 % 40.0 % 2.7 % 6.9 % 0.0 % 0.8 %
Pseudomonadaceae 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % 68.1 % 0.0 % 0.0 % 0.0 % 0.0 % 0.0 %
Tenericutes Erysipelotrichaceae 0.0 % 0.1 % 0.0 % 1.5 % 0.1 % 0.0 % 0.0 % 2.6 % 0.0 % 0.3 % 0.0 % 0.0 % 0.0 % 1.5 %
Othera 0.1 % 0.7 % 0.5 % 2.4 % 0.5 % 0.8 % 1.2 % 0.2 % 0.4 % 0.3 % 4.3 % 1.2 % 0.7 % 2.6 %
aIncludes family-level taxa that were either unassigned or represented <1.0 % abundance in each of the 14 samples











Lactobacilli have been shown to provide some inhibition
activity against several common food pathogens [39]. Al-
though it remains unclear whether the reduction of benefi-
cial bacteria such as Lactobacillus spp. can increase
susceptibility to BTPC colonization in infants, this finding
illustrates a distinct feature of the gut microbiota profile in
infants once BTPC colonization has been established.
Mariat et al. [40] illustrated the utility of using
phylum-level abundance ratios to profile the infant gut
microbiota. In that study, it was reported that the ratio
of Firmicutes/Bacteroidetes in healthy infants was signifi-
cantly lower than that of adults. Although we did not
observe a significant difference in Firmicutes/Bacteroi-
detes abundance ratios between our sample groups, we
do report a significant decrease in the abundance ratio
of Firmicutes/Proteobacteria in confirmed infant botu-
lism samples; a ratio which was 515-times lower than
that observed in samples from non-confirmed cases.
Whether this reduction preceded BTPC colonization, or
whether it was a consequence of botulism could not be
concluded. It should be noted that phylum abundances
could have been influenced by gaps in sample collection
(the time between onset of illness and sample collection)
and sample storage times prior to DNA extractions.
Nevertheless, taxonomic analysis indicated that the pri-
mary disparity between confirmed and non-confirmed
samples resulted from significant differences in the rela-
tive abundances of Firmicutes and Proteobacteria within
the fecal microbiota.
Only a handful of studies have reported their efforts to
characterize the fecal microflora in infants with botu-
lism. Long et al. (1985) [27] examined stool samples
from seven infant botulism patients and found a high
proportion of enterobacteria in the fecal microflora.
Similarly, we report significantly higher Enterobacteria-
ceae abundance in the fecal microflora of infants with
botulism compared to samples from non-confirmed
cases. A comparison of family-level abundances revealed
Enterobacteriaceae to be the only bacterial family which
displayed a significant disparity between confirmed and
non-confirmed samples. Enterobacteriaceae was the
Table 4 Percent Clostridium botulinum and Clostridium baratii
16S rRNA gene sequences observed for each sample




Confirmed CDC68129 0.0 9.4 × 10−4
CDC68058 7.3 × 10−6 8.6 × 10−4
CDC69068 0.0 0.0
CDC68083 6.7 × 10−5 0.0
CDC68116 5.8 × 10−5 4.5 × 10−6
CDC68192 3.4 × 10−3 3.2 × 10−3
CDC68090 1.0 × 10−2 0.0
CDC68126 1.1 × 10−4 2.7 × 10−6
Non-confirmed CDC68053 0.0 5.7 × 10−6
CDC69114 0.0 0.0
CDC68112 1.7 × 10−6 0.0
CDC68122 2.3 × 10−5 6.3 × 10−4
CDC69078 0.0 0.0
CDC69062 0.0 0.0
Fig. 5 Phylum-level abundance percentages relative to age. Abundance measurements based on 16S rRNA gene sequence reads and assigned
by alignment with Greengenes ribosomal database using an OTU definition of 97 % sequence homology with a minimum cluster size of 3.
Samples representing infants younger than the overall mean infant age of 87.9 days include CDC68129, CDC68058, CDC9068, CDC68083,
CDC68116, CDC68192, CDC68053, CDC69114, and CDC68112, and samples representing infants older than the overall mean infant age of
87.9 days include CDC68090, CDC68126, CDC68122, CDC69062, and CDC69078. Ages are based on the age of the infant at the time of sample
collection. The asterisk indicates a significant difference in phylum abundance was calculated between the two age groups
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most abundant bacterial family identified in the fecal
microbiota of infants with botulism averaging 44.0 % of
total bacterial family abundance. In contrast, Enterobac-
teriaceae abundance in non-confirmed samples averaged
only 8.4 % of all bacterial families identified, making it
the fifth most abundant family within that group. This
disparity is not surprising as this family of Gammapro-
teobacteria contains many gut pathogens which are re-
sponsible for a variety of gastrointestinal illnesses and
can flourish in the gastrointestinal tract of infants with
systemic infections [41–43]. Long et al. suggested that
an enterobacteria-enriched infant gut may reflect a tran-
sitional stage of development where susceptibility to C.
botulinum colonization is increased. This transition may
be driven by dietary changes among the infants, or due
to factors that have yet to be determined. Nonetheless,
these findings could indicate a possible link between in-
fant botulism and Enterobacteriaceae colonization; how-
ever, with only a limited number of studies available for
comparison, follow-up investigations would be required
to establish a clear trend.
In another study, Wilcke et al. [26] quantified C. botu-
linum from stool samples of four infants with laboratory-
confirmed infant botulism and found that C. botulinum
abundance ranged from 0.01 to 3.3 % of culturable fecal
microbiota. In our study, neither C. botulinum nor C.
baratii ever exceeded 0.01 % of the fecal microbiota.
Although it is likely that BTPC intestinal abundance
fluctuates temporally over the course of the illness,
these findings do support the widely-held assumption
that botulism can manifest from a relatively limited
presence of BTPC in the infant gut. Unfortunately,
there is no available data to indicate whether there is a
minimum threshold for BTPC colonization needed to
produce an amount of toxin required for disease onset.
Given the extremely high potency of BoNT these or-
ganisms are capable of producing, coupled with the low
weight of infants relative to adults, it was not surprising
Fig. 6 RDA ordination diagram displaying the associations between samples, phylum abundance, and age. Crosses represent confirmed samples,
and circles represent non-confirmed samples. The solid red vector was generated from age data representing the age of the infant at the time of
sample collection, and blue vectors represent phylum-level abundances. Each vector points in the direction of steepest increase of value, and the
length of each vector indicates the measure of fit for each sample relative to the vector. Angles between vectors indicate the correlation between
the individual factors. Approximate correlations are positive when the angle is <90° and negative when the angle is >90°
Table 5 Primers used for 16S rRNA gene amplification of gDNA extracted from stools
Fusion PCR Primer Sequencing adapters Library key 16S rRNA Gene target region Target name
Aforward 5’-CCATCTCATCCCTGCGTGTCTCCGAC TCAG CCTACGGGAGGCAGCAG-3’ P1
trP1 forward 5’-CCTCTCTATGGGCAGTCGGTGAT – CCTACGGGAGGCAGCAG-3’ P1
Areverse 5’-CCATCTCATCCCTGCGTGTCTCCGAC TCAG ATTACCGCGGCTGCT-3’ P2
trP1 reverse 5’-CCTCTCTATGGGCAGTCGGTGAT – ATTACCGCGGCTGCT-3’ P2
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to find no more than 0.01 % BTPC abundance in stool
samples from infant botulism patients.
The identification of C. botulinum and C. baratii 16S
rRNA gene sequences in both botulism-confirmed and
non-confirmed samples highlight the current limitations
of using a sequencing-based approach for botulism diag-
nostics. Infant botulism is confirmed by the laboratory
detection of BoNT and/or the detection of BTPC in in-
fant stool. Although C. baratii can produce BoNT sub-
type F, non-toxigenic strains are more commonly
isolated from stools. Non-toxigenic C. baratii do not har-
bor the serotype F botulinum neurotoxin gene (bont/F)
within their genome, and as a result, 16S rRNA gene
sequencing does not provide the necessary resolution
to distinguish between toxigenic and non-toxigenic
isolates of this organism. Similarly, amplicon sequen-
cing cannot resolve C. botulinum from non-toxigenic
strains of clostridia (such as C. sporogenes) that
share >99 % 16S rRNA gene identity.
The temporal development of the infant gut micro-
biota throughout the first year of life is not consistent
across all individuals [7, 8]. This yearlong progression
from near sterility to a fully developed microbiome is
guided by a myriad of external factors and can be inter-
rupted by illness [6, 10, 44]. With the exception of Pro-
teobacteria abundance, the microbiota in the younger
infant group did not significantly differ from that of the
older infant group in composition, abundance, or diver-
sity. RDA indicates a negative correlation between infant
age and samples with higher Proteobacteria abundance,
and a positive correlation between infant age and sam-
ples with higher abundances of Actinobacteria, Teneri-
cutes,Verrumicrobia, and Bacteroidetes. Excluding age as
a co-variable in RDA (data not shown) did not alter the
cluster patterns shown in Fig. 6, nor the correlations ap-
proximated between samples and phylum composition
and abundance. Together, these findings indicate that
differences in fecal microbiota abundance and compos-
ition between botulism-confirmed and non-confirmed
samples were not due solely to patient age disparities.
Conclusions
The infant gut microbiota undergoes a dramatic transi-
tion throughout the first year of life, and a variety of fac-
tors guide its development. Perturbations of the infant
gut microbiota have been shown to increase susceptibil-
ity to opportunistic pathogens, yet it remains unclear
whether similar disturbances can be associated with in-
creased susceptibility to BTPC colonization. Researchers
have speculated that infants display an increased suscep-
tibility to botulism due to their transient and minimally
complex gut microbiota; however, there is little pub-
lished data to support this claim. In an effort to resolve
some of the uncertainty surrounding this speculation,
we conducted the first detailed analysis into the gut micro-
biota of infants with botulism using high-throughput, next-
generation sequencing technology.
We have identified several distinct features among
BTPC-colonized microbiota which are comparable to
those previously identified in infants suffering from botu-
lism and other enteric diseases. Our findings revealed that,
compared to that of non-confirmed samples, the fecal
microbiota of infants with botulism contained signifi-
cantly higher abundances of Proteobacteria and Entero-
bacteriaceae, while Firmicutes abundance remained
significantly lower. Additionally, our findings indicated
that botulinum toxin-producing clostridia were present
in very low abundances, indicating that botulism can
manifest from a relatively limited presence of these or-
ganisms in the infant gut.
These findings can be used to guide future infant botu-
lism research efforts by directing focus toward several
distinct features of the infant gut microbiota which have
been identified here. The data generated from this study
has greatly expanded our insight into the gut microbiota
profiles in infant botulism patients. Ultimately, our under-
standing of infant botulism will continue to increase as
sequencing technologies and computational analyses are
further developed. These developments should greatly
increase our capabilities as investigators interested in gain-
ing a deeper understanding of botulism and its influence
on children impacted by this disease.
Methods
Sample properties and patient characteristics
In compliance with a human subjects exemption proto-
col (#4991.0) approved by the CDC Human Research
Protection Office, coded stool samples were selected for
investigation from 14 infants suspected to have botulism
with patient ages ranging from 14 to 350 days old. The
samples were selected to represent a broad array of sam-
ple properties and patient characteristics. Of the 14 sam-
ples sent for botulism testing, NBLT confirmed 8
samples for infant botulism (confirmed), while 6 could
not be confirmed (non-confirmed). Refer to Table 1 for
complete sample properties and patient characteristics.
Genomic DNA extraction and sequencing
Genomic DNA was extracted from each stool sample
using the PowerFood® Microbial DNA Isolation Kit (MO
BIO Laboratories, Inc., Carlsbad, CA). Libraries were
prepared for Ion Torrent PGM sequencing following the
Fusion Method—Ion Amplicon Library Preparation for
bidirectional sequencing (Ion Amplicon Library Prepar-
ation [Fusion Method] User Guide; Publication number
4468326, Revision C). Extracted gDNA was purified
using the DNA Clean and Concentrator-5 kit (Zymo
Research, Irvine, CA) and quantified on a NanoDrop
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2000 UV–vis Spectrophotometer (Thermo Scientific,
Wilmington, DE). For bidirectional sequencing, two dir-
ect PCR amplifications targeting the hypervariable V3
region of the 16S rRNA gene were performed on each
sample gDNA. PCR target primers were previously de-
scribed by Zhang et al. [45] and synthesized with Ion
Torrent compatible adaptors and key sequences to gen-
erate approximately 280 bp PCR amplicons (Table 5).
Each 50 μL PCR reaction consisted of 45 μL of Platinum
PCR SuperMix High Fidelity buffer (Life Technologies,
Grand Island, NY), 1 μL each of 10 μM primers and
50 ng of purified gDNA. PCR thermocycling conditions
was set up with an initial denaturation at 94 °C for
2 min followed by 35 cycles of 94 °C for 30 s, 58 °C for
30 s, and 68 °C for 30 s with a final extension of 68 °C
for 2 min. Following amplification, PCR products were
purified using the DNA Clean and Concentrator-5 kit
(Zymo Research), and size selection on the purified
amplicons was performed using the E-Gel Agarose Gel
Electrophoresis System (Life Technologies). Each size-
selected library was quantified using the Qubit dsDNA
HS Assay Kit (Life Technologies), diluted to 18 pM, and
pooled into an equimolar solution. Each DNA fragment
library was templated onto Ion Sphere Particles (ISPs)
via emulsion PCR using the Ion OT2 instrument, and
the resulting template-positive ISPs were quality checked
to assess templating efficiency. Template-positive ISPs
were enriched on the Ion ES instrument, loaded onto
Ion 314 v2 chips, and sequenced using the Ion PGM.
Genomic DNA from Microbial Mock Community B
(Even, High Concentration), v. 5.1H (bei Resources) was
used to evaluate the effects of amplification and sequen-
cing bias. The mock community sample of gDNA con-
sisted of a single pool of equimolar RNA operon counts
from 20 bacterial strains representing 5 bacterial phyla.
Library preparation, sequencing, and taxonomic analysis
of the mock community DNA was performed in the
same manner as stool sample gDNA. A phylum-level
comparison of actual abundance (known phylum percent
distribution of the mock community) versus observed
abundance (PGM sequencing results) was performed.
The formula below was used to calculate mean absolute
percentage error (MAPE) in abundance quantification









Raw sequence data and the associated metadata for all
14 samples have been deposited in MG-RAST metage-
nomics analysis server (http://metagenomics.anl.gov). All
sample data is freely available and openly accessible from
the MG-RAST website under project number 13930, or
by navigating directly to http://metagenomics.anl.gov/
metagenomics.cgi?page=MetagenomeProject&project=
13930.
Sequence analysis and taxonomic characterization
Sequence reads were analyzed with the open source soft-
ware package Quantitative Insights into Microbial Ecology
v1.8.0 (QIIME) [46]. Prior to analysis, reads with a read
length of less than 150 bp or greater than 350 bp, reads
with missing quality scores or mean quality scores below
25, reads with primer mismatches, and reads with greater
than 6 ambiguous bases were removed from analysis. The
remaining reads were aligned using Python Nearest Align-
ment Space Determination (PyNAST), and clustered into
operational taxonomic units (OTUs). OTU clustering is a
metric of binning sequence reads where a single OTU is
defined as a subset of reads (minimum cluster size of 3)
which share 97 % or greater sequence homology. The
QIIME workflow used for this analysis can be accessed via
https://github.com/tbshirey/QIIME.
The representative taxonomic identities were assigned
by alignment with the Greengenes ribosomal database
[47], and stacked histograms of the relative taxonomic
abundances were generated showing phylum-level taxo-
nomic representatives for each sample. Family-level per-
cent abundances, Enterobacteriaceae abundance, and
abundance of two expected BTPC (C. botulinum and C.
baratii) were also recorded for each sample. Phylum-
level ratios of Firmicutes/Proteobacteria and Firmicutes/
Bacteroidetes were calculated based on average abun-
dance percentages for each sample. Bacteroidetes was
not detected in samples CDC68129 and CDC68192
which prevented calculation of the Firmicutes/Bacteroi-
detes ratio for these samples.
Statistical analyses
Significance testing was performed using the Mann-
Whitney U rank-sum test in Statistical Package for the
Social Sciences (SPSS; IBM Corporation, Armonk, NY).
A non-parametric 0.95 confidence interval (α = 0.05) ac-
companied these estimates. Linear regression (reported
as the adjusted R2 value; R̅2) was performed in SPSS to
model the correlation between taxonomic abundance
and infant age. Shannon diversity index illustrating
inter-sample fecal microflora taxa diversity was calcu-
lated in QIIME by rarifying all samples. This index is a
commonly used measure of diversity which uses an algo-
rithm to account for both species richness (i.e., the num-
ber of species present) and species evenness (i.e., the
distribution of species) within a sample. The Shannon
diversity index estimates diversity on a scale beginning
at 0 (no diversity observed) and increasing where greater
diversity is estimated.
RDA was performed using the software package Canoco
4.5 (Microcomputer Power, Ithaca, New York) to examine
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the relationships between sample microbiota community
structure, disease confirmation, and infant age. Bacterial
phyla (dotted blue vectors) served as response variables,
and patient age at the time of sample collection (solid red
vector) was used as a predictor co-variable. Sample sym-
bols were generated to indicate disease confirmation
(crosses = botulism confirmed samples; circles = non-
confirmed samples). Vector length is proportional to
abundance (phylum vectors) or age (age vector), with each
variable increasing in the direction of the vector. Correla-
tions between samples and vectors are approximated
based on sample proximity to each vector (indicating cor-
relation between the sample and phylum composition
and/or age), and the location of the sample point along
the length of each vector (indicating correlation between
the sample and phylum abundance, and/or age). Prior to
ordination, Monte Carlo permutation tests (499 permuta-
tions under reduced model) were performed on non-
transformed data. RDA was visualized using CanoDraw™
(Microcomputer Power). All other data visualized in ta-
bles, histograms, and bar charts were managed in Micro-
soft Excel (Microsoft, Redmond, WA), and box plots were
generated using R (http://cran.r-project.org/).
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